Mustang Bio

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 28, 2024
AstraZeneca, Exercise, Fortification, New Drug Application, Patient, GBM, CRL, NDA, Menkes, Minocycline, Therapy, Marketing, Radiation, CKPT, Rosacea, Investigational New Drug, Erythema, Safety, BLA, Fortress Biotech, Food, Red, Amyloidosis, Dermatology, Carcinoma, FDA, Hyperhidrosis, Mustang Bio, Menkes disease, PDUFA, Pharmaceutical industry

MIAMI, March 28, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

Key Points: 
  • Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “In 2023, we built a significant amount of momentum to position our Company to achieve multiple milestones in 2024.
  • In March 2024, the FDA accepted the NDA and has set a PDUFA goal date of November 4, 2024.
  • In December 2023, the FDA issued a complete response letter (“CRL”) for the cosibelimab BLA.
  • Fortress’ consolidated net revenue totaled $84.5 million for the full year ended December 31, 2023, which included $59.7 million in net revenue generated from our marketed dermatology products.

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Tuesday, November 14, 2023
Sale, Associate, Translation, Research, Safety, Foreign investment, Food, Transaction, WM, First grade, CRS, IND, Disease, Glioblastoma, Risk, Waldenström macroglobulinemia, Clinical trial, GBM, Patient, CD19, Nature, FDA, Follicular lymphoma, University of Washington, Chronic lymphocytic leukemia, File, Mustang, Diagnosis, University, Mustang Bio, Cancer, Society, CFIUS, Letter, DSM-IV codes, Lymphoma, AACR, Cytokine release syndrome, Indolent lymphoma, Pharmaceutical industry, Cryptocurrency, Video game

WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter that ended September 30, 2023.

Key Points: 
  • WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter that ended September 30, 2023.
  • Subsequent to the end of the third quarter, Mustang raised approximately $4.4 million of gross proceeds in a registered direct offering completed in October 2023.
  • Research and development expenses were $9.5 million for the third quarter of 2023, compared to $15.5 million for the third quarter of 2022.
  • General and administrative expenses were $2.1 million for the third quarter of 2023, compared to $3.4 million for the third quarter of 2022.

Runway Growth Finance Corp. Provides Second Quarter 2023 Portfolio Update

Retrieved on: 
Tuesday, July 11, 2023
Communication, Investment, Private law, IO, Internet of things, ASX, Cardiac resynchronization therapy, Internet, Partial, Mustang Bio, AI, Completion, EBR, INRIX, Software, Airline, Financial services, Security (finance), Bank, Elevate

WOODSIDE, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the second quarter ended June 30, 2023.

Key Points: 
  • WOODSIDE, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the second quarter ended June 30, 2023.
  • Runway Growth is poised to capitalize on select opportunities in the second half of 2023.”
    In the second quarter of 2023, Runway Growth funded four new investments in existing portfolio companies.
  • During the second quarter ended June 30, 2023, Runway Growth experienced four prepayments totaling $88.7 million and scheduled principal amortization of $2.8 million.
  • As of June 30, 2023, the Runway Growth portfolio included 33 debt investments to 31 portfolio companies and 58 equity investments in 43 portfolio companies, including 25 portfolio companies where Runway Growth holds both a debt and equity investment.

Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, May 15, 2023
CLL, Fortress Biotech, Checkpoint, Mustang Bio, Gout, Waldenström macroglobulinemia, Dotinurad, Radiation, Arm, Triplex, Fortification, Cytomegalovirus, Chronic lymphocytic leukemia, Follicular lymphoma, Biologics license application, Fred Hutchinson Cancer Research Center, ICML, Menkes disease, CKPT, New Drug Application, Clinical trial, Lymphoma, NDA, Prescription Drug User Fee Act, Prescription, Urica, WM, CAR, Waldenström, International Conference on Afghanistan, London (2010), Patient, Risk, Hyperuricemia, PD-1, FDA, Death, BLA, Conference, Rosacea, Safety, Disease, Pharmaceutical industry, Mastic (plant resin), PDUFA

MIAMI, May 15, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.

Key Points: 
  • In March 2023, the FDA accepted the BLA filing for cosibelimab and set a PDUFA goal date of January 3, 2024.
  • Journey Medical’s total product net revenues were $12.2 million for the first quarter of 2023, compared to first quarter 2022 total product net revenues of $20.8 million.
  • On a non-GAAP basis, Fortress research and development expenses were $2.3 million for the first quarter of 2023, compared to $2.8 million for first quarter of 2022.
  • On a non-GAAP basis, Fortress selling, general and administrative expenses were $7.0 million, for the first quarter of 2023, compared to $6.2 million for the first quarter of 2022.

Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 30, 2023
Rosacea, Fortress Biotech, Waldenström macroglobulinemia, Fortification, CD19, MACR, Chronic lymphocytic leukemia, Stanford University, Fred Hutchinson Cancer Research Center, CKPT, Prescription, Chemistry, Dermatology, Acquisition, Patient, Division, Carcinoma, BLA, Disease, CLL, Gout, FACP, Urica, B-cell lymphoma, IGA, Cytokine release syndrome, PDUFA, Growth, PD-1, FDA, Death, Biologics license application, Dotinurad, Safety, CAR, Hyperuricemia, CR, Mustang Bio, Therapy, ORR, Checkpoint, Fuji, Radiation, Follicular lymphoma, Menkes disease, Clinical trial, NDA, WM, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Mustang, Food, Pharmaceutical industry, Cryptocurrency, Mastic (plant resin)

Fortress has also established 25 acquisition companies with expert opinion leaders in multiple therapeutic areas over the past year.

Key Points: 
  • Fortress has also established 25 acquisition companies with expert opinion leaders in multiple therapeutic areas over the past year.
  • In June 2022, we announced that the topline results of Checkpoint’s pivotal trial of cosibelimab in metastatic cSCC were presented at the 2022 American Society of Clinical Oncology Annual Meeting.
  • Also in June 2022, we announced positive interim results from Checkpoint’s pivotal trial of cosibelimab in locally advanced cSCC.
  • In July 2022, we announced that David Jin, who has served as Vice President of Corporate Development since May 2020, was also appointed as Chief Financial Officer effective August 16, 2022.

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Wednesday, March 29, 2023
CLL, Mustang Bio, Waldenström macroglobulinemia, Mayo Clinic, CD19, Chronic lymphocytic leukemia, Follicular lymphoma, Fred Hutchinson Cancer Research Center, Disclosure, Clinical trial, Research, Translation, WM, CAR, Waldenström, Hematological Cancer Research Investment and Education Act, Cytokine release syndrome, Patient, CR, Clinical professor, FDA, TS, Mustang, ORR, DSM-IV codes, Safety, Pharmaceutical industry, Cryptocurrency

WORCESTER, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2022.

Key Points: 
  • WORCESTER, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2022.
  • 2022 and Recent Corporate Highlights:
    In March 2022, Mustang completed a $75 million debt financing with Runway Growth Capital.
  • In June 2022, Mustang announced that the FDA granted Orphan Drug Designation to MB-106 for the treatment of WM, a rare type of B-NHL.
  • Additionally, in October 2022, Mustang shared interim data from 28 patients treated in the initial, ongoing Phase 1/2 investigator-sponsored clinical trial at Fred Hutch.

Lykan Bioscience Appoints Barbara Ressler, Ph.D. as Vice President, Manufacturing Process Sciences

Retrieved on: 
Tuesday, September 20, 2022
Mustang Bio, Editas Medicine, Biomedical engineering, CGMP, Process, Patient, CEO, Technology, Cell, CDMO, Science, Massachusetts Institute of Technology, Mechanical, Mechanical engineering, Lists of diseases, GMP, Hematological Cancer Research Investment and Education Act, Fine chemical, W Motors Lykan HyperSport, Northwestern University

HOPKINTON, Mass., Sept. 20, 2022 /PRNewswire/ -- Lykan Bioscience, an innovative contract development and manufacturing organization (CDMO) focused on cell-based therapies, today welcomes Barbara Ressler, Ph.D. as Vice President, Manufacturing Process Sciences.

Key Points: 
  • HOPKINTON, Mass., Sept. 20, 2022 /PRNewswire/ -- Lykan Bioscience, an innovative contract development and manufacturing organization (CDMO) focused on cell-based therapies, today welcomes Barbara Ressler, Ph.D. as Vice President, Manufacturing Process Sciences.
  • "At Lykan, we are building a contract development and manufacturing organization focused on analytical and process science innovation to enable the cost-effective delivery of cell therapies to the patients that need them," said Patrick Lucy, President and CEO of Lykan Bioscience.
  • "I'm excited to join Lykan to expand our process science capabilities, so that our partners can develop, scale-out, and scale-up GMP compliant processes and deliver well-characterized products to their patients" said Barbara Ressler, Vice President, Manufacturing Process Sciences.
  • Lykan Bioscience is an innovative contract development and manufacturing services organization (CDMO) focused on cell-based therapies.

Genomenon Wins Best of Show at Bio-IT World Conference & Expo 2022

Retrieved on: 
Thursday, May 12, 2022
DNA, Best, Disease, Patient, Decision-making, Degenerative disease, Artificial intelligence, Research, Lists of diseases, Industry, Clinical trial, Awareness, Life, Conference, Mustang Bio, Genomics, Cancer, CEO, Medical device, Pharmaceutical industry, Diagnosis

ANN ARBOR, Mich., May 12, 2022 /PRNewswire-PRWeb/ -- Genomenon® Inc., an AI-driven genomics company, today announced that Bio-IT World has awarded them Best of Show for Disease-Specific Curated Content, now in the Mastermind® Genomic Search Engine. Genomenon's offering was one of 27 products considered for this prestigious award at last week's Bio-IT World Conference & Expo in Boston.

Key Points: 
  • Genomenon's offering was one of 27 products considered for this prestigious award at last week's Bio-IT World Conference & Expo in Boston.
  • Bio-IT World's Best of Show awards program recognizes the best of the innovative product solutions for the life sciences industry.
  • "We are honored to be recognized as Best of Show at Bio-IT this year," said Mike Klein, CEO of Genomenon.
  • Keeping pace with the ever-evolving body of genomic knowledge, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery.

Runway Growth Finance Provides First Quarter 2022 Portfolio Update

Retrieved on: 
Thursday, April 7, 2022
Private Securities Litigation Reform Act, Risk, IO, Organization, Exercise, Sale, Investment, Mustang Bio, Growth, Internet, Completion, Ownership, Research, Woman, FiscalNote, AI, CEO, U.S. Securities and Exchange Commission, EPIC, Security (finance), MTBC, LLC, Translation, Johnson & Johnson, Lists of diseases, Artificial intelligence, Technology, Industry, Hematological Cancer Research Investment and Education Act, Nasdaq, COVID-19, GLOBE, Investment Company Act of 1940, IOT, Student, Securities & Exchange Commission of Pakistan, Solution, Information services, CareCloud, Fidelis, Bank, Pharmaceutical industry, Medicine, Video game, Revelle, MD

WOODSIDE, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Runway Growth) (Nasdaq: RWAY), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced a portfolio update for the first quarter ended March 31, 2022.

Key Points: 
  • WOODSIDE, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Runway Growth) (Nasdaq: RWAY), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced a portfolio update for the first quarter ended March 31, 2022.
  • Runway Growth capitalized on its strong momentum in the first quarter, utilizing proceeds from our revolving credit facility to complete seven new investments, strategically increase leverage and drive strong portfolio growth amidst increasing market uncertainty, said David Spreng, Founder and CEO of Runway Growth.
  • In the first quarter of 2022, Runway Growth funded seven investments: two investments in new portfolio companies, and five new investments in existing portfolio companies.
  • About Runway Growth Finance Corp.
    Runway Growth is a growing specialty finance company focused on providing flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity.

City of Hope to Present Late-Breaking and Clinical Trial Data at AACR: Cell Therapy and Preventive Medicine

Retrieved on: 
Friday, April 8, 2022
Oncology, Health, Hospitals, Clinical Trials, Research, Science, Biotechnology, LinkedIn, Human, Glioblastoma, Organization, City of Hope, Acute myeloid leukemia, Gene expression, AML, National Cancer Institute, Immunotherapy, Clinical trial, Haematopoietic system, Translational Genomics Research Institute, Mouse, Survival, Liver, Research, FLT3, CAR, Program, American Association, Neoplasm, Topical steroid withdrawal, Cancer, Mark (given name), Brain, Association, Technology, Diabetes, Twitter, Smoking, Mustang Bio, City, YouTube, Cancer Treatment Centers of America, Instagram, University, Patient, Disease, UAB, Large-cell lung carcinoma, A Call for Unity, Pharmaceutical industry, Vaccine, Hope, Facebook

The treatment could one day provide a viable cell therapy option for patients with AML, who traditionally have not benefited from innovative cell therapy treatments.

Key Points: 
  • The treatment could one day provide a viable cell therapy option for patients with AML, who traditionally have not benefited from innovative cell therapy treatments.
  • When these patients experience relapse, it often occurs rapidly, so there is not enough time to prepare patient-derived chimeric antigen receptor (CAR) T cell therapy.
  • Christine Brown will present data to support the initiation of a Phase 1 clinical trial combining CAR T cell therapy with a cancer-killing oncolytic viral therapy for the treatment of recurrent glioblastoma.
  • This combination trial builds on interim clinical findings from City of Hope and the University of Alabama at Birmingham (UAB).